Comparative Pharmacology
Head-to-head clinical analysis: PROVAYBLUE versus SODIUM NITRITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROVAYBLUE versus SODIUM NITRITE.
PROVAYBLUE vs SODIUM NITRITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylthioninium chloride (methylene blue) acts by reducing methemoglobin to hemoglobin via the enzyme NADPH methemoglobin reductase, thereby restoring oxygen-carrying capacity of the blood.
Sodium nitrite is a vasodilator that acts by relaxing vascular smooth muscle, primarily through the generation of nitric oxide (NO). It also converts hemoglobin to methemoglobin, which binds cyanide, thereby acting as an antidote for cyanide poisoning.
1-2 mg/kg intravenously over 5 minutes, may repeat once if needed. Maximum single dose: 300 mg.
300 mg (10 mL of a 30 mg/mL solution) intravenously over 2-4 minutes, followed immediately by sodium thiosulfate. May repeat once after 30-60 minutes if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours. In patients with renal impairment, half-life may be prolonged; no dose adjustment recommended for mild-to-moderate impairment, but use caution in severe impairment.
Terminal half-life: 0.5–1 hour (nitrite); due to rapid oxidation to nitrate, which has a half-life of 5–8 hours. Clinically, methemoglobin reduction requires monitoring for 2–4 hours.
Primarily renal excretion as unchanged drug. Approximately 45-60% of a dose is excreted unchanged in urine. Minor fecal elimination accounts for less than 10%.
Primarily renal; 60-70% as nitrate and unchanged nitrite; minor biliary (<5%) and fecal (<2%) elimination.
Category C
Category C
Antidote
Antidote